| Literature DB >> 29533784 |
Alexandra Garancher1, Charles Y Lin2, Morgane Morabito1, Wilfrid Richer3, Nathalie Rocques1, Magalie Larcher1, Laure Bihannic4, Kyle Smith5, Catherine Miquel6, Sophie Leboucher7, Nirmitha I Herath1, Fanny Dupuy1, Pascale Varlet8, Christine Haberler9, Christine Walczak10, Nadine El Tayara10, Andreas Volk10, Stéphanie Puget11, François Doz12, Olivier Delattre13, Sabine Druillennec1, Olivier Ayrault1, Robert J Wechsler-Reya14, Alain Eychène1, Franck Bourdeaut15, Paul A Northcott16, Celio Pouponnot17.
Abstract
Cancer cells often express differentiation programs unrelated to their tissue of origin, although the contribution of these aberrant phenotypes to malignancy is poorly understood. An aggressive subgroup of medulloblastoma, a malignant pediatric brain tumor of the cerebellum, expresses a photoreceptor differentiation program normally expressed in the retina. We establish that two photoreceptor-specific transcription factors, NRL and CRX, are master regulators of this program and are required for tumor maintenance in this subgroup. Beyond photoreceptor lineage genes, we identify BCL-XL as a key transcriptional target of NRL and provide evidence substantiating anti-BCL therapy as a rational treatment opportunity for select MB patients. Our results highlight the utility of studying aberrant differentiation programs in cancer and their potential as selective therapeutic vulnerabilities.Entities:
Keywords: BCL2; CRX; MAF; NRL; apoptosis; medulloblastoma; photoreceptor; retina
Mesh:
Substances:
Year: 2018 PMID: 29533784 PMCID: PMC6368680 DOI: 10.1016/j.ccell.2018.02.006
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743